Antithymocyte Globulin

Table of contents

  • Brand Names
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Latvia: Atgam; Slovenia: Atgam.

North America

Canada: Atgam; USA: Atgam.

Latin America

Mexico: Atgam.


Japan: Lymphoglobuline.

Drug combinations


Pharmacologic Category

Immunosuppressive Agents; Immune Globulin. (ATC-Code: L04AA03).

Mechanism of action

May involve elimination of antigen-reactive T lymphocytes (killer cells) in peripheral blood or alteration of T-cell function.

Therapeutic use

Prevention and treatment of acute renal allograft rejection. Treatment of moderate to severe aplastic anemia in patients not considered suitable candidates for bone marrow transplantation.

Pregnancy and lactiation implications

Use during pregnancy is not recommended. Use with caution during lactation.

Unlabeled use

Prevention and treatment of other solid organ allograft rejection. Prevention of graft vs host disease following bone marrow transplantation.


Hypersensitivity to lymphocytic immune globulin, any component of the formulation, or other equine γ-globulins.

Warnings and precautions

Hypersensitivity and anaphylactic reactions can occur. Rash, dyspnea, hypotension, or anaphylaxis precludes further administration of the drug. Discontinue if severe and unremitting leukopenia or unremitting thrombocytopenia occur. Must be administered via central line due to chemical phlebitis. Intradermal skin testing is recommended prior to first-dose administration.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart